Rob Bell

Rob Bell is a co-founder and CEO of Telo Therapeutics, Inc., a company established in December 2015 that focuses on precision medicine to reverse cancer cell immortality by targeting telomerase. Prior to this role, Rob Bell served as a postdoctoral researcher at UCSF, concentrating on therapeutic strategies to disrupt telomerase activity in Glioblastoma. Rob Bell earned a PhD in Biomedical Sciences from UCSF, where the dissertation explored the activation mechanisms of TERT promoter mutations in various cancer types, following an undergraduate degree in Biology from Boston College. Additional experience includes research roles at Boston College, TransMolecular, and Stanford University, with a focus on computational analysis and gene data.